{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:56:23Z","timestamp":1790686583302,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.lungcan.2019.02.002","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T01:46:11Z","timestamp":1549244771000},"page":"84-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma"],"prefix":"10.1016","volume":"130","author":[{"given":"Yun L.","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing Qing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.lungcan.2019.02.002_bib0005","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1200\/JCO.2012.43.9422","article-title":"MET as a possible target for non-small-cell lung cancer","volume":"31","author":"Sadiq","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2019.02.002_bib0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jtho.2016.10.014","article-title":"Targeting MET in lung Cancer: will expectations finally Be MET","volume":"12","author":"Drilon","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2019.02.002_bib0015","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1097\/JTO.0000000000000478","article-title":"MET mutation associated with responsiveness to crizotinib","volume":"10","author":"Waqar","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2019.02.002_bib0020","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1097\/JTO.0000000000000491","article-title":"MET-mutated NSCLC with major response to crizotinib","volume":"10","author":"Mendenhall","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2019.02.002_bib0025","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1097-2765(01)00378-1","article-title":"Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein","volume":"8","author":"Peschard","year":"2001","journal-title":"Mol. Cell"},{"issue":"9","key":"10.1016\/j.lungcan.2019.02.002_bib0030","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","article-title":"Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations","volume":"11","author":"Schrock","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2019.02.002_bib0035","article-title":"Antitumor activity and safety of crizotinib in patients with advanced MET exon 14-altered non-small cell lung cancer","author":"Drilon","year":"2016","journal-title":"C ASCO"},{"issue":"12","key":"10.1016\/j.lungcan.2019.02.002_bib0040","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1158\/1078-0432.CCR-16-0229","article-title":"MET exon 14 alterations in lung cancer: exon skipping extends half-life","volume":"22","author":"Drilon","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.lungcan.2019.02.002_bib0045","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1158\/2159-8290.CD-14-1467","article-title":"Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping","volume":"5","author":"Paik","year":"2015","journal-title":"J. Cancer Discov."},{"issue":"4","key":"10.1016\/j.lungcan.2019.02.002_bib0050","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/0008-5472.CAN-04-2650","article-title":"Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer","volume":"65","author":"Ma","year":"2005","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2019.02.002_bib0055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1615\/JEnvironPatholToxicolOncol.v30.i4.70","article-title":"MET and phosphorylated MET as potential biomarkers in lung cancer","volume":"30","author":"Tretiakova","year":"2011","journal-title":"J. Environ. Pathol. Toxicol. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2019.02.002_bib0060","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1200\/JCO.2015.63.4600","article-title":"MET exon 14 mutations in non-small-cell lung cancer Are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression","volume":"34","author":"Awad","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219303071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219303071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T04:05:47Z","timestamp":1555041947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219303071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":12,"alternative-id":["S0169500219303071"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.02.002","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}